文献速递贫血与红细胞疾病MDS 与骨髓增殖性肿瘤

克隆性造血可能先于再生障碍性贫血诊断数年出现

Clonal hematopoiesis may precede the diagnosis of aplastic anemia by several years.
PubMed 文献 · Blood Adv · 2026-01-01

在英国生物银行2006至2022年前瞻性匹配队列中,克隆性造血者14 471例与无克隆性造血匹配者144 323例相比,再生障碍性贫血风险升高(HR 2.72,95%CI 2.16-3.43);SRSF2、TET2、ASXL1、DNMT3A突变者风险更高。

要点

  • 克隆性造血个体再生障碍性贫血风险升高,HR 2.72(95%CI 2.16-3.43)。
  • SRSF2突变者再生障碍性贫血风险最高,HR 19.35(95%CI 11.07-33.80)。
  • TET2、ASXL1、DNMT3A突变者再生障碍性贫血风险亦升高。

核心结论

  • 克隆性造血可能先于再生障碍性贫血诊断出现,尤其在携带SRSF2、TET2、ASXL1和DNMT3A突变者中。
  • 需要进一步研究以理解该关联的本质及克隆性造血与再生障碍性贫血之间可能的共同致病机制。

研究设计与样本

  • 英国生物银行2006至2022年前瞻性匹配队列研究。
  • 基于全外显子组测序数据确定克隆性造血个体14 471例,并按性别、出生年份和族裔随机匹配无克隆性造血个体144 323例。
  • 采用Cox回归模型计算克隆性造血与再生障碍性贫血的风险比(HR)及95%置信区间(CI)。

主要发现

  • 克隆性造血个体再生障碍性贫血风险高于参照组(HR 2.72;95%CI 2.16-3.43)。
  • SRSF2突变者再生障碍性贫血风险HR 19.35(95%CI 11.07-33.80)。
  • TET2突变者再生障碍性贫血风险HR 4.45(95%CI 3.14-6.29)。
  • ASXL1突变者再生障碍性贫血风险HR 2.06(95%CI 1.06-4.00)。
  • DNMT3A突变者再生障碍性贫血风险HR 1.88(95%CI 1.31-2.70)。

局限性

  • 需要进一步研究以理解该关联的本质及克隆性造血与再生障碍性贫血之间可能的共同致病机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aplastic anemia (AA) is a bone marrow failure syndrome resulting from the immune destruction of hematopoietic stem cells. Clonal hematopoiesis (CH) is characterized by expansion of progenitor hematopoietic stem cells that harbor leukemogenic driver mutations. It has previously been shown that individuals with AA have a high prevalence of CH. However, the association between CH and AA remains unknown. We conducted a prospective, matched cohort study within the UK Biobank from 2006 to 2022. Individuals with CH were ascertained based on whole-exome sequencing data. For each individual with CH, we randomly selected 10 individuals without CH matched by sex, birth year, and ethnicity from the study population. We calculated hazard ratios (HRs) and 95% confidence intervals (CIs) of AA associated with CH using a Cox regression model. We also studied the association by different mutations of CH. We identified 14 471 individuals with CH, and 144 323 matched individuals free of CH. Individuals with CH had a higher risk of AA (HR, 2.72; 95% CI, 2.16-3.43) than the reference group. The increase was greater for individuals with CH mutations in SRSF2 (HR, 19.35; 95% CI, 11.07-33.80), TET2 (HR, 4.45; 95% CI, 3.14-6.29), ASXL1 (HR, 2.06; 95% CI, 1.06-4.00), or DNMT3A (HR, 1.88; 95% CI, 1.31-2.70). In conclusion, CH may precede the diagnosis of AA, particularly in those with SRSF2, TET2, ASXL1, and DNMT3A mutations. Further studies are needed to understand the nature of this association and potential shared pathogenic mechanisms between CH and AA.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Liu Q, Fang F, Xue H, et al. Clonal hematopoiesis may precede the diagnosis of aplastic anemia by several years. Blood Adv. 2026. PMID: 41296017. doi:10.1182/bloodadvances.2024015776

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。